Strongbridge Biopharma plc
SBBP · NASDAQ
12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 41.5% | 20.4% | 155.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 92.8% | 82.4% | 77.9% | 79% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -125.8% | -196.1% | 289.2% | -1,452.8% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -146.7% | -227.8% | 176.7% | -1,610.6% |
| EPS Diluted | -0.8 | -0.89 | 0.64 | -3.11 |
| % Growth | 10.1% | -239.1% | 120.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |